Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate

BACKGROUND/AIMS: The protease inhibitors, nafamostat and gabexate, have been used to prevent pancreatitis related to endoscopic retrograde cholangiopancreatography (ERCP). In vitro, nafamostat inhibits the pancreatic protease activities 10-100 times more potently than gabexate. We evaluated the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Jae Hyuck, Lee, In Seok, Kim, Hyung Keun, Cho, Yu Kyung, Park, Jae Myung, Kim, Sang Woo, Choi, Myung-Gyu, Chung, In-Sik
Formato: Texto
Lenguaje:English
Publicado: The Korean Society of Gastroenterology; the Korean Society of Gastrointestinal Endoscopy; the Korean Association for the Study of the Liver; the Korean Society of Neurogastroenterology and Motility; Korean Association for the Study of Intestinal Diseases; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Society of Pancreatobiliary Diseases 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852705/
https://www.ncbi.nlm.nih.gov/pubmed/20431747
http://dx.doi.org/10.5009/gnl.2009.3.3.205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852705/
https://www.ncbi.nlm.nih.gov/pubmed/20431747
http://dx.doi.org/10.5009/gnl.2009.3.3.205

Ejemplares similares